Aplus Biotechnology Corporation Limited

Total Valuation

Aplus Biotechnology Corporation Limited carries a market capitalization of 2.53B, placing it among publicly traded companies globally. Its enterprise value stands at 2.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Aplus Biotechnology Corporation Limited currently has 30.47M shares outstanding.

Valuation Ratios

Aplus Biotechnology Corporation Limited trades at a trailing price-to-earnings ratio of 20.84. The price-to-sales ratio is 4.20, and the price-to-book ratio stands at 6.67.

Enterprise Valuation

On an enterprise value basis, Aplus Biotechnology Corporation Limited trades at an EV/EBITDA multiple of 15.31 and an EV/FCF ratio of 15.26. The EV/Sales ratio of 3.77 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.31 provides insight into valuation relative to core operating earnings.

Financial Position

Aplus Biotechnology Corporation Limited maintains a current ratio of 3.27, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.08, indicating elevated leverage, while an interest coverage ratio of 89.28 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Aplus Biotechnology Corporation Limited posts a return on equity of 64.00 and a return on invested capital of 32.64.

Taxes

Over the trailing twelve months, Aplus Biotechnology Corporation Limited has paid 38.08M in income taxes, reflecting an effective tax rate of 19.34.

Stock Price Statistics

Aplus Biotechnology Corporation Limited's stock has declined approximately -22.84528% over the past 52 weeks. The 50-day moving average sits at 74.10, while the 200-day moving average is 82.00.

Income Statement

Over the trailing twelve months, Aplus Biotechnology Corporation Limited generated 788.05M in revenue and converted that into 158.83M in net income, yielding earnings per share of 5.21. EBITDA reached 194.18M, while operating income came in at 194.18M.

Balance Sheet

Aplus Biotechnology Corporation Limited holds 438.31M in cash and equivalents against 102.09M in total debt, resulting in a net debt position of -316.20M. Total book value stands at 496.30M, with working capital of 657.44M providing operational flexibility.

Cash Flow

Aplus Biotechnology Corporation Limited produced 185.40M in operating cash flow over the past twelve months. After subtracting -7.72M in capital expenditures, free cash flow totaled 177.68M - equivalent to 5.82 per share.

Margins

Aplus Biotechnology Corporation Limited operates with a gross margin of 69.81, reflecting its pricing power and cost economics. The operating margin of 24.64 and net profit margin of 20.15 provide insight into operational efficiency.

Dividends & Yields

Scores

Aplus Biotechnology Corporation Limited posts an Altman Z-Score of 7.26, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.